The US Food and Drug Administration (FDA) has approved a label expansion to Teva’s Ajovy in certain children and adolescents, ...

FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children ...

The U.S. Food and Drug Administration on Tuesday approved Ajovy, an injection made by Israeli drugmaker Teva Pharma , to help ...

The FDA has approved Ajovy (fremanezumab) for the prevention of episodic migraine in pediatric patients aged 6 to 17 years weighing at least 45kg.

Ajovy becomes the first-and-only calcitonin gene-related peptide agonist approved for pediatric patients aged six to 17 years ...

The FDA expanded the indication for fremanezumab (Ajovy) injection for episodic migraine prevention to include children and ...

Teva Pharmaceutical (NYSE:TEVA) announced on Wednesday that the U.S. Food and Drug Administration (FDA) approved its migraine therapy Ajovy for children and adolescents, expanding its previous label ...

Teva Pharmaceutical has received a green light from the US regulator for its biologic Ajovy (fremanezumab) to be used for ...

PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced today that the U.S. Food ...

The FDA approved Ajovy for adults in 2018. Israel-based Teva narrowly missed having the first CGRP-targeting drug approved for migraines at the time, following Novartis and Amgen’s Aimovig ...

The Food and Drug Administration (FDA) has approved Ajovy ® (fremanezumab-vfrm) for the preventive treatment of episodic migraine in pediatric patients aged 6 to 17 years weighing at least 45kg ...